Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
CC-5013-MM-017 is a Phase I, multicenter study to determine the maximum tolerated dose (MTD),
safety profile, pharmacokinetics, and preliminary efficacy of lenalidomide with and without
dexamethasone in Japanese subjects with previously treated MM. The study will consist of two
cohorts: 1) Monotherapy "Maximum Tolerated Dose (MTD) Determination" Cohort; and 2)
"Combination Treatment" Cohort.